Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Rises By 48.6%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 37,152 shares, an increase of 48.6% from the February 12th total of 24,997 shares. Approximately 5.2% of the shares of the company are short sold. Based on an average daily trading volume, of 810,829 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily trading volume, of 810,829 shares, the days-to-cover ratio is currently 0.0 days. Approximately 5.2% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Bluejay Diagnostics Trading Down 4.0%

NASDAQ:BJDX opened at $1.90 on Monday. The company has a market cap of $1.84 million, a P/E ratio of 0.00 and a beta of 0.72. Bluejay Diagnostics has a twelve month low of $1.70 and a twelve month high of $40.80. The company’s 50-day moving average price is $2.61 and its 200-day moving average price is $4.98.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings data on Friday, March 6th. The company reported $3.23 earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). 18.47% of the stock is currently owned by hedge funds and other institutional investors.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.